Empagliflozin, a sodium-glucose cotransporter inhibitor, improved heart remodeling and mesenteric artery endothelial function in the metabolic syndrome with HFpEF ZSF1 rat: Role of cyclooxygenases
Titel:
Empagliflozin, a sodium-glucose cotransporter inhibitor, improved heart remodeling and mesenteric artery endothelial function in the metabolic syndrome with HFpEF ZSF1 rat: Role of cyclooxygenases
Auteur:
Park, S.H. Farooq, M.A. Gaertner, S. Bruckert, C. Qureshi, A. Lee, H. Benrahla, D. Pollet, B. Stephan, D. Ohlmann, P. Mayoux, E. Auger, C. Morel, O. Schini-Kerth, V.B.